Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
“Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said Pamela di Cenzo, Vice President, General Manager, Rare Disease, Canada at Acadia. “If granted marketing authorization, trofinetide will be the first option available to treat Rett syndrome in Canada.”
Health Canada grants Priority Review for drug submissions intended for the treatment, prevention, or diagnosis of serious, life-threatening, or severely debilitating illnesses or conditions for which there is substantial evidence of clinical effectiveness that the drug addresses an unmet medical need or provides a benefit/risk profile that is improved over existing therapies.
“O.R.S.A. is pleased that Health Canada has granted Priority Review for this promising treatment which, if approved, would be a significant step forward in addressing the unmet medical needs of Canadians living with Rett syndrome,” said Sabrina Millson, President of the Ontario Rett Syndrome Association (O.R.S.A.). “Our community of patients, caregivers and supporters are excited at the prospect of having a treatment option for Rett syndrome.”
The Health Canada filing is supported by results from the positive pivotal Phase 3 LAVENDER™ study evaluating the efficacy and safety of trofinetide versus placebo in 187 girls and young women with Rett syndrome. The co-primary endpoints were change from baseline in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score, a caregiver assessment, and Clinical Global Impression–Improvement (CGI-I) scale score, clinician perspective, at week 12; both were statistically significant. The key secondary endpoint measuring improvements in communication was also statistically significant. Trofinetide has been approved for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States, and it is not currently authorized for sale in Canada for the treatment of Rett syndrome.
https://www.businesswire.com/news/home/20240422998763/en/
- Forums
- ASX - By Stock
- NEU
- TROFINETIDE PRIORITY REVIEW IN CANADA
TROFINETIDE PRIORITY REVIEW IN CANADA
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.13 |
Change
-0.430(2.76%) |
Mkt cap ! $1.981B |
Open | High | Low | Value | Volume |
$15.61 | $15.93 | $15.12 | $3.180M | 206.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 300 | $15.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.15 | 796 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 288 | 15.120 |
8 | 759 | 15.110 |
7 | 1363 | 15.100 |
3 | 413 | 15.090 |
4 | 603 | 15.080 |
Price($) | Vol. | No. |
---|---|---|
15.140 | 1425 | 24 |
15.150 | 1208 | 15 |
15.160 | 2324 | 12 |
15.170 | 890 | 10 |
15.180 | 446 | 4 |
Last trade - 13.43pm 20/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |